trans-AUCB
| 规格 | 价格 | 货期 | 数量 |
|---|---|---|---|
| 5mg | ￥1479.00 | 10-15工作日发货 | |
| 10mg | ￥2601.00 | 10-15工作日发货 | |
| 50mg | ￥9363.00 | 10-15工作日发货 |
特色产品
- 适用于流式细胞仪和荧光显微镜检测
- 准确区分活细胞/凋亡细胞/坏死细胞
- 用于免疫印迹和质谱分析等后续操作
- 适用于30 KDa-130 KDa大小的蛋白
- 对细胞无毒性
- 步骤更简单，无需有机溶剂
- 可将信号灵敏度提高100倍
- 同时保持稳定的特异性和分辨率
- 提供更高的转录效率并抑制免疫激活
- 使用5-moUTP和Cy5-utp修饰
- 优异的扩增效率、可重复性和稳定性
- 卓越的灵敏度和准确性，操作简单
- 优化的缓冲液和T7 RNA聚合酶混合物
- 20 μL反应体系可获得更高的RNA产量
产品描述
IC50: 0.5 nM
trans-AUCB is a potent inhibitor of soluble epoxide hydrolase (sEH).
Soluble epoxide hydrolase (sEH) can convert epoxides to their corresponding diols. Inhibitors of sEH have anti-hypertensive, anti-inflammatory, neuroprotective, and cardioprotective effects.
In vitro: A previous study showed that the pretreatment with DAPT could substantially potentiate the growth inhibition caused by t-AUCB in U251 and U87 cells. Moreover, the pretreatment with DAPT markedly increased t-AUCB-induced apoptosis of U251 and U87 cells. Moreover, T-AUCB alone did not obviously affect caspase-3 activity in the cells, but t-AUCB plus DAPT pretreatment caused significant increase of caspase-3 activity. In addition, the pretreatment with DAPT was able to completely block t-AUCB-induced phosphorylation of p38 MAPK, MAPKAPK2 and Hsp27 in the cells [1].
In vivo: A previous animal study was conducted to investigate the effects of acute sEH inhibition by t-AUCB on infarct volume, functional outcome, and changes in cerebral blood flow (CBF) in a rat model of ischemic stroke. It was found that t-AUCB could significantly reduce cortical infarct volume by 35%, elevate cumulative epoxyeicosatrienoic acids-to-dihydroxyeicosatrienoic acids ratio in brain cortex by twofold, and improve functional outcome in arm-flexion test when compared with that of the vehicle-treated group [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Li JY, Li RJ, Wang HD. γ-secretase inhibitor DAPT sensitizes t-AUCB-induced apoptosis of human glioblastoma cells in vitro via blocking the p38 MAPK/MAPKAPK2/Hsp27 pathway. Acta Pharmacol Sin. 2014 Jun;35(6):825-31.
[2] Shaik JS, Ahmad M, Li W, Rose ME, Foley LM, Hitchens TK, Graham SH, Hwang SH, Hammock BD, Poloyac SM. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1605-13.
产品性质
| 物理外观 | A crystalline solid |
| CAS号 | 885012-33-9 |
| 分子式 | C24H32N2O4 |
| 分子量 | 412.5 |
| 化学名称 | 4-[[trans-4-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]cyclohexyl]oxy]-benzoic acid |
| 溶解度 | ≤30mg/ml in DMSO;20mg/ml in dimethyl formamide |
| SMILES | OC(c(cc1)ccc1O[C@H](CC1)CC[C@@H]1NC(NC1(C[C@H](C2)C3)C[C@H]3CC2C1)=O)=O |
| 存储条件 | -20°C |
| 运输条件 | 蓝冰 |
产品应用 (实验数据来自文献，APExBIO并未验证，仅供参考)
IC50和靶点
| 生物活性描述 | 反式-AUCB（t-AUCB）是一种强效、口服活性和选择性可溶性环氧化物水解酶（sEH）抑制剂，对 hsEH、小鼠 sEH 和大鼠 sEH 的 IC50 分别为 1.3 nM、8 nM 和 8 nM。 |
生物相关数据
质量控制
操作说明
APExBIO 顾客使用本产品发表的 1 篇科研文献
- 1. Xu-shun Jiang, Xing-yang Xiang, et al. "Inhibition of soluble epoxide hydrolase attenuates renal tubular mitochondrial dysfunction and ER stress by restoring autophagic flux in diabetic nephropathy." Cell Death and Disease (2020) 11:385.
沪公网安备 31011002003500